Jaguar Animal Health (JAGX) : 2 analysts are covering Jaguar Animal Health (JAGX) and their average rating on the stock is 1.5, which is read as a Strong Buy. 1 equity analysts believe that the stock has a bright future and the price doesnt capture all of its upside, hence they rate the stock as a Strong Buy. Jaguar Animal Health (JAGX) also receives 1 more Buy recommendations from analysts who believe that the stock will do well going forward. A Zacks Investment Research rank of 3, which recommends a Hold affirms that they expect a large upside in the stock from the current levels.
Jaguar Animal Health (JAGX) : The most positive equity analysts on Jaguar Animal Health (JAGX) expects the shares to touch $10, whereas, the least positive believes that the stock will trade at $4 in the short term. The company is covered by 2 Wall Street Brokerage Firms. The average price target for shares are $6.75 with an expected fluctuation of $4.6 from the mean.
For the current week, the company shares have a recommendation consensus of Buy.
Jaguar Animal Health (NASDAQ:JAGX): The stock opened at $1.29 and touched an intraday high of $1.37 on Wednesday. During the day, the stock corrected to an intraday low of $1.2101, however, the bulls stepped in and pushed the price higher to close in the green at $1.23 with a gain of 0.82% for the day. The total traded volume for the day was 256,627. The stock had closed at $1.22 in the previous trading session.
Jaguar Animal Health, Inc. is a development-stage animal health company focused on developing and commercializing gastrointestinal products for companion and production animals. The Companys pipeline of prescription drug product candidates includes Canalevia, species-specific formulations of crofelemer, Virend and species-specific formulations of NP-500. The Companys non-prescription products comprises of Neonorm Calf and species-specific formulations of Neonorm. Canalevia is the lead prescription drug product candidate for the treatment of various forms of watery diarrhea in dogs. The Company develops Virend for the treatment of herpes virus in cats. Neonorm Calf is used to improve gut health and normalize stool formation in preweaned dairy calves with scours.